548 related articles for article (PubMed ID: 17324532)
21. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
[TBL] [Abstract][Full Text] [Related]
22. Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence.
Chung HH; Jo H; Kang WJ; Kim JW; Park NH; Song YS; Chung JK; Kang SB; Lee HP
Gynecol Oncol; 2007 Mar; 104(3):529-34. PubMed ID: 17049971
[TBL] [Abstract][Full Text] [Related]
23. Influence of FDG-PET on computed tomography-based radiotherapy planning for locally recurrent nasopharyngeal carcinoma.
Zheng XK; Chen LH; Wang QS; Wu HB; Wang HM; Chen YQ; Yan WP; Li QS; Xu YK
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1381-8. PubMed ID: 17869450
[TBL] [Abstract][Full Text] [Related]
24. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
25. [The values of MRI, CT, and PET-CT in detecting retropharyngeal lymph node metastasis of nasopharyngeal carcinoma].
Tang LL; Ma J; Chen Y; Zong JF; Sun Y; Wang Y; Wu HB; Cui NJ
Ai Zheng; 2007 Jul; 26(7):737-41. PubMed ID: 17626750
[TBL] [Abstract][Full Text] [Related]
26. The clinical impact of [(18)F]FDG PET/CT for the management of recurrent endometrial cancer: correlation with clinical and histological findings.
Chung HH; Kang WJ; Kim JW; Park NH; Song YS; Chung JK; Kang SB
Eur J Nucl Med Mol Imaging; 2008 Jun; 35(6):1081-8. PubMed ID: 18180917
[TBL] [Abstract][Full Text] [Related]
27. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
Thrall MM; DeLoia JA; Gallion H; Avril N
Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284
[TBL] [Abstract][Full Text] [Related]
28. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
[TBL] [Abstract][Full Text] [Related]
29. Whole-body 18F-FDG PET in recurrent or metastatic nasopharyngeal carcinoma.
Yen RF; Hong RL; Tzen KY; Pan MH; Chen TH
J Nucl Med; 2005 May; 46(5):770-4. PubMed ID: 15872349
[TBL] [Abstract][Full Text] [Related]
30. Detection and restaging of residual and/or recurrent nasopharyngeal carcinoma after chemotherapy and radiation therapy: comparison of MR imaging and FDG PET/CT.
Comoretto M; Balestreri L; Borsatti E; Cimitan M; Franchin G; Lise M
Radiology; 2008 Oct; 249(1):203-11. PubMed ID: 18710963
[TBL] [Abstract][Full Text] [Related]
31. Influence of [18F] fluorodeoxyglucose positron emission tomography on salvage treatment decision making for locally persistent nasopharyngeal carcinoma.
Zheng XK; Chen LH; Wang QS; Wu FB
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1020-5. PubMed ID: 16730131
[TBL] [Abstract][Full Text] [Related]
32. Impact of FDG-PET to detect recurrence of head and neck squamous cell carcinoma.
Périé S; Hugentobler A; Susini B; Balogova S; Grahek D; Kerrou K; Montravers F; Chater PE; St Guily JL; Talbot JN
Otolaryngol Head Neck Surg; 2007 Oct; 137(4):647-53. PubMed ID: 17903585
[TBL] [Abstract][Full Text] [Related]
33. Impact of [18F]-2-fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients.
Fleming AJ; Smith SP; Paul CM; Hall NC; Daly BT; Agrawal A; Schuller DE
Laryngoscope; 2007 Jul; 117(7):1173-9. PubMed ID: 17603315
[TBL] [Abstract][Full Text] [Related]
34. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF
Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905
[TBL] [Abstract][Full Text] [Related]
35. Screening for distant metastases before salvage surgery in patients with recurrent head and neck squamous cell carcinoma: a retrospective case series comparing thoraco-abdominal CT, positron emission tomography and abdominal ultrasound.
Fakhry N; Michel J; Colavolpe C; Varoquaux A; Dessi P; Giovanni A
Clin Otolaryngol; 2012 Jun; 37(3):197-206. PubMed ID: 22520870
[TBL] [Abstract][Full Text] [Related]
36. Three-Dimensional Image Fusion of
Yu Y; Zhang WB; Liu XJ; Guo CB; Yu GY; Peng X
J Oral Maxillofac Surg; 2017 Jun; 75(6):1301.e1-1301.e15. PubMed ID: 28320612
[TBL] [Abstract][Full Text] [Related]
37. FDG PET/CT in the management of nasopharyngeal carcinoma.
Mohandas A; Marcus C; Kang H; Truong MT; Subramaniam RM
AJR Am J Roentgenol; 2014 Aug; 203(2):W146-57. PubMed ID: 25055290
[TBL] [Abstract][Full Text] [Related]
38. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient.
Lonneux M; Lawson G; Ide C; Bausart R; Remacle M; Pauwels S
Laryngoscope; 2000 Sep; 110(9):1493-7. PubMed ID: 10983949
[TBL] [Abstract][Full Text] [Related]
39. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
[TBL] [Abstract][Full Text] [Related]
40. Impact of FDG-PET/CT imaging on nodal staging for head-and-neck squamous cell carcinoma.
Murakami R; Uozumi H; Hirai T; Nishimura R; Shiraishi S; Ota K; Murakami D; Tomiguchi S; Oya N; Katsuragawa S; Yamashita Y
Int J Radiat Oncol Biol Phys; 2007 Jun; 68(2):377-82. PubMed ID: 17321066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
